Topic: clinical trial data
The ASK1 inhibitor was no better than placebo at improving fibrosis, wiping out hopes that selonsertib would spearhead Gilead’s push into a new field.
The treatment failed to have the hoped-for effects on patients with the rare disease MPS II, causing investors to drive Sangamo’s stock down 30%.
The anti-HER2 antibody improved PFS by more than Herceptin, teeing MacroGenics up to file for approval in the second half of the year.
The anti-CD38 antibody prolonged progression-free survival over standard of care, providing a boost for Sanofi’s shift toward in-house programs.
The PharmaMar unit failed to link the siRNA eye drops to improved scores on scales of ocular pain and corneal staining compared to artificial tears.
VOS failed to best the tolerability of Allergan's Restasis but delivered superior efficacy, suggesting it may have an unexpected edge over its rival.
Shares in the nanocap biotech shot up more than 100% in premarket trading before falling away somewhat as people dug deeper into the data.
The failure wiped two-thirds off the value of Aptinyx, which went public last year with a $118 million IPO.
The dual PDE3/PDE4 inhibitor failed to beat placebo on a measure of lung function, wiping more than 30% off Verona’s share price.